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1. INTRODUCTION {#mgg3650-sec-0005}
===============

Endometrial cancer is the most common type of gynecological malignancy worldwide and has a large geographic variation in incidence and mortality rates (Bray et al., [2018](#mgg3650-bib-0004){ref-type="ref"}). In China, there has been a significant increase in the number of women diagnosed with endometrial cancer (Chen et al., [2016](#mgg3650-bib-0006){ref-type="ref"}). Although early menarche, unopposed estrogen, endometriosis, late menopause, obesity, diabetes, hypertension, and nulliparity are well‐known risk factors for the development of endometrial cancer (Amant et al., [2005](#mgg3650-bib-0001){ref-type="ref"}), only a part of individuals exposed to these risk factors develop endometrial cancer during their lifetime, suggesting that genetic factor plays a crucial role in endometrial cancer development. The single nucleotide polymorphism (SNP) is the most common form of human genetic variations. It has been reported that polymorphisms of interleukin genes are significantly associated with gynecologic cancers risk (Koensgen et al., [2015](#mgg3650-bib-0012){ref-type="ref"}; Yu et al., [2015](#mgg3650-bib-0028){ref-type="ref"}; Zhou et al., [2018](#mgg3650-bib-0029){ref-type="ref"}). Recently, genome‐wide association analysis studies have identified many risk loci in the candidate endometrial cancer susceptibility genes, such as *HNF1B* (Painter et al., [2015](#mgg3650-bib-0018){ref-type="ref"}), *LOC643623*, *AKT1*, and *KLF5* (Burki, [2016](#mgg3650-bib-0005){ref-type="ref"}; Cheng et al., [2016](#mgg3650-bib-0007){ref-type="ref"}). However, the mechanism of endometrial cancer is still unclear.

The association between inflammation and cancer have been recognized for some years and recently become the focus of tumor studies (Grivennikov, Greten, & Karin, [2010](#mgg3650-bib-0010){ref-type="ref"}). It has also indicated the proinflammatory milieu can directly increase estrogen production, which may facilitate carcinogenesis by disrupting the estrogen‐progesterone balance (Modugno, Ness, Chen, & Weiss, [2005](#mgg3650-bib-0017){ref-type="ref"}). A growing number of studies reported that SNPs locus in interleukin (IL) genes, such as *IL‐32* (Yu et al., [2015](#mgg3650-bib-0028){ref-type="ref"}), *IL‐6* (Wang, Zhang, Zheng, Liu, & Li, [2016](#mgg3650-bib-0024){ref-type="ref"}), and *IL1A* (Yu et al., [2016](#mgg3650-bib-0027){ref-type="ref"}), are associated with the risk endometrial cancer. Interleukin 1 receptor type 2 (IL‐1R2) is located on the long arm of human chromosome 2 at band 2q12, belongs to the interleukin 1 receptor family (Boraschi & Tagliabue, [2013](#mgg3650-bib-0003){ref-type="ref"}). *IL‐1R2*serves as a negative regulator of *IL‐1* signaling by competing with *IL‐1R1*for *IL‐1* and by complexing with *IL‐1* receptor accessory protein (IL‐1RAP) once it binds *IL‐1*, thereby sequestering both the ligand and the accessory protein required for signal transduction (Lang et al., [1998](#mgg3650-bib-0013){ref-type="ref"}). *IL‐1R2* is an important mediator involved in many cytokine induced immune and inflammatory responses (Peters, Joesting, & Freund, [2013](#mgg3650-bib-0019){ref-type="ref"}).

Association studies between *IL‐1R2*gene polymorphisms and diseases have been carried out recently (Ren, Dong, Huyan, Jin, & Chen, [2018](#mgg3650-bib-0021){ref-type="ref"}; Xia et al., [2015](#mgg3650-bib-0025){ref-type="ref"}; Xie et al., [2017](#mgg3650-bib-0026){ref-type="ref"}). However, the influence of *IL‐1R2*polymorphisms on endometrial cancer susceptibility in the Chinese Han population has not been reported yet. Given the role of *IL‐1R2* in immune regulation and inflammatory response, we hypothesized that common genetic polymorphisms in the *IL‐1R2* gene may also influence the risk of endometrial cancer. To investigate this hypothesis, we recruited 293 patients with endometrial cancer and 579 healthy controls to investigate the association between polymorphisms in the *IL‐1R2* gene and endometrial cancer risk in the Chinese Han women population.

2. MATERIALS AND METHODS {#mgg3650-sec-0006}
========================

2.1. Study participants {#mgg3650-sec-0007}
-----------------------

In this case‐control study, a total of 293 female patients with new diagnosis of endometrial cancer were recruited from the Hainan General Hospital and the Northwest Women and Children Hospital. All cases were confirmed histologically to have endometrial cancer. The patients were recruited without restrictions of age, sex, or disease stage. The controls were 579 females randomly selected from a pool of healthy volunteers who visited the general health check‐up center at the same hospitals during the same period. The mean age of the participants was 48.06 years in the control group and 59.31 years in the case group, respectively. Women who have a history of any cancer or hysterectomy were excluded in the study. The case and control subjects were Chine Han population.

This study was performed in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Hainan General Hospital and the Northwest Women and Children Hospital. All of the participants voluntarily agreed to participate in this study and all provided written informed consent.

2.2. Genotyping {#mgg3650-sec-0008}
---------------

We collected 5ml peripheral blood samples from each subject using venipuncture into ethylene diamine tetraacetic acid (EDTA)‐coated blood vacutainer collection tubes and then stored at −80°C for further use. We used the GoldMag‐Mini Whole Blood Genomic DNA Purification Kit (GoldMag. Co. Ltd., Xi\'an, China) to extract genomic DNA from blood samples following the manufacturer\'s instructions. We assessed the purity and concentration of the extracted DNA using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA) by absorbance measurements at 260 and 280 nm.

Six SNPs (rs11674595, rs4851527, rs719250, rs3218896, rs3218977, and rs2072472) in *IL‐1R2*with minor allele frequency (MAF) greater than 0.05 in the global population from the HapMap database and previously reported were adopted for analysis. We used the Agena Bioscience Assay Design Suite V2.0 software (<https://agenacx.com/online-tools/>) to design the primers of PCR amplification and extension of the six selected SNPs. These SNPs in *IL‐1R2*were genotyped in the case and control groups using the Agena MassARRAY platform with iPLEX gold chemistry (Agena Bioscience, San Diego, CA) according to the manufacture\'s instructions. We used the Agena Bioscience TYPER software (version 4.0) to manage and analyze data.

2.3. Statistical analysis {#mgg3650-sec-0009}
-------------------------

The Hardy--Weinberg equilibrium (HWE) was performed for each polymorphism among controls using the PLINK software (version 1.07) (Purcell et al., [2007](#mgg3650-bib-0020){ref-type="ref"}). We compared the distributions of SNPs allele and genotype frequencies between cases and controls using *χ* ^2^ test. The association analyses were conducted using logistic regression analysis under codominant, dominant, recessive, and additive genetic models with adjustment for age. Pair‐wise linkage disequilibrium (LD) between the five SNPs was assessed using the Haploview software (version 4.2) (Barrett, Fry, Maller, & Daly, [2005](#mgg3650-bib-0002){ref-type="ref"}). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the potential association between SNPs and endometrial cancer risk (Lin et al., [2017](#mgg3650-bib-0014){ref-type="ref"}; Tian et al., [2018](#mgg3650-bib-0023){ref-type="ref"}). *p* value less than 0.05 was considered statistically significant. All statistical tests were two‐sided. The statistical analyses were performed using the Statistical Package of the Social Sciences (SPSS) software version 20.0 (SPSS Inc., Chicago, IL).

3. RESULTS {#mgg3650-sec-0010}
==========

The distributions of the genotype frequency of the six SNPs among the healthy controls were found to be in accordance with the HWE (*p* \> 0.05). We used Pearson *χ* ^2^ test to compare the distributions of the allele frequency of the SNPs in *IL‐1R2* between the case group and the control group (Table [1](#mgg3650-tbl-0001){ref-type="table"}). However, the allele frequency of all the six SNPs in case group did not differ significantly compared to that in the control group (*p* \> 0.05). There was no statistically significant association between the *IL‐1R2*polymorphisms and endometrial cancer risk in the Chinese Han population.

###### 

Alleles distribution of *IL‐1R2*polymorphisms and association with endometrial cancer risk

  SNP‐ID       Chr   Position    Alleles A/B   MAF     HWE‐*p*   OR (95%CI)   *p*                 
  ------------ ----- ----------- ------------- ------- --------- ------------ ------------------- -------
  rs11674595   2     101994530   C/T           0.222   0.222     0.718        1.00 (0.78--1.27)   0.978
  rs4851527    2     102005914   A/G           0.265   0.307     0.284        0.81 (0.65--1.01)   0.063
  rs719250     2     102007256   A/G           0.319   0.301     0.201        1.09 (0.88--1.35)   0.448
  rs3218896    2     102015190   C/T           0.166   0.136     0.596        1.27 (0.96--1.67)   0.091
  rs3218977    2     102024739   A/G           0.249   0.225     0.095        1.15 (0.91--1.45)   0.252
  rs2072472    2     102026557   C/T           0.240   0.216     0.326        1.15 (0.90--1.45)   0.260

95% CI: 95% Confidence interval; A: Minor allele; B: Major allele; Chr: chromosome; HWE: Hardy Weinberg equilibrium; MAF: Minor allele frequency; OR: Odds ratio; SNP: Single nucleotide polymorphism.

*p* values were calculated from *χ* ^2^ test ( two sided).

*p \< *0.05 was considered statistically significant.
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Next, we further evaluated the association between the *IL‐1R2*polymorphisms and endometrial cancer risk under the genetic models (codominant, dominant, recessive, and additive) by logistic regression analysis adjusting for age (Table [2](#mgg3650-tbl-0002){ref-type="table"}). Compared with the GG wild‐type homozygous genotype, the AG genotype of rs4851527 was associated with a decreased risk of endometrial cancer (OR = 0.71, 95% CI: 0.52--0.96, *p* = 0.028). When the wild‐type homozygous genotype GG was used as a reference, the variant homozygote AA and heterozygote AG genotypes were also found to be associated with a reduced risk of endometrial cancer in the dominant model (OR = 0.71, 95% CI: 0.53--0.96, *p* = 0.024). Similar association was found between rs4851527 and the risk of endometrial cancer in the additive model (OR = 0.79, 95% CI: 0.63--1.00, *p* = 0.047).

###### 

Genetic model analyses of the association between *IL‐1R2* polymorphisms and endometrial cancer risk

  SNP--ID      Model        Genotype   Case                Control             Without adjust OR (95%CI)   *p*                 Adjust OR (95%CI)   *p*
  ------------ ------------ ---------- ------------------- ------------------- --------------------------- ------------------- ------------------- -----
  rs11674595   Codominant   TT         182                 350                 1.00                                            1.00                 
  CT           89           196        0.87 (0.64--1.19)   0.388               0.90 (0.65--1.24)           0.515                                   
  CC           20           30         1.28 (0.71--2.32)   0.412               1.21 (0.65--2.25)           0.548                                   
  Dominant     TT           182        350                 1.00                                            1.00                                    
  CC + CT      109          226        0.93 (0.69--1.24)   0.612               0.94 (0.70--1.27)           0.699                                   
  Recessive    TT + CT      271        546                 1.00                                            1.00                                    
  CC           20           30         1.34 (0.75--2.41)   0.322               1.25 (0.68--2.31)           0.468                                   
  Additive     --           --         --                  1.00 (0.79--1.26)   0.979                       1.00 (0.78--1.27)   0.977               
  rs4851527    Codominant   GG         163                 272                 1.00                                            1.00                 
  AG           105          258        0.68 (0.50--0.92)   0.011               0.71 (0.52--0.96)           0.028                                   
  AA           25           49         0.85 (0.51--1.43)   0.544               0.74 (0.43--1.28)           0.280                                   
  Dominant     GG           163        272                 1.00                                            1.00                                    
  AA + AG      130          307        0.71 (0.53--0.94)   0.016               0.71 (0.53--0.96)           0.024                                   
  Recessive    GG + AG      268        530                 1.00                                            1.00                                    
  AA           25           49         1.01 (0.61--1.67)   0.972               0.86 (0.51--1.46)           0.580                                   
  Additive     --           --         --                  0.81 (0.65--1.01)   0.063                       0.79 (0.63--1.00)   0.047               
  rs719250     Codominant   GG         137                 289                 1.00                                            1.00                 
  AG           125          231        1.14 (0.85--1.54)   0.384               1.25 (0.92--1.71)           0.152                                   
  AA           31           59         1.11 (0.69--1.79)   0.674               1.20 (0.73--1.97)           0.470                                   
  Dominant     GG           137        289                 1.00                                            1.00                                    
               AA + AG      156        290                 1.14 (0.86--1.50)   0.379                       1.24 (0.93--1.67)   0.145               
  Recessive    GG + AG      262        520                 1.00                                            1.00                                    
  AA           31           59         1.04 (0.66--1.65)   0.858               1.08 (0.67--1.74)           0.745                                   
  Additive     --           --         --                  1.08 (0.88--1.34)   0.458                       1.15 (0.92--1.43)   0.215               
  rs3218896    Codominant   TT         203                 433                 1.00                                            1.00                 
  CT           81           133        1.30 (0.94--1.79)   0.112               1.41 (1.00--1.97)           0.048                                   
  CC           8            12         1.42 (0.57--3.53)   0.448               1.50 (0.58--3.85)           0.401                                   
  Dominant     TT           203        433                 1.00                                            1.00                                    
  CC + CT      89           145        1.31 (0.96--1.79)   0.091               1.41 (1.02--1.96)           0.037                                   
  Recessive    TT + CT      284        566                 1.00                                            1.00                                    
  CC           8            12         1.33 (0.54--3.29)   0.539               1.37 (0.54--3.51)           0.509                                   
  Additive     --           --         --                  1.26 (0.96--1.66)   0.094                       1.34 (1.01--1.79)   0.043               
  rs3218977    Codominant   GG         163                 341                 1.00                                            1.00                 
  AG           111          216        1.08 (0.80--1.44)   0.631               1.05 (0.77--1.43)           0.747                                   
  AA           17           22         1.62 (0.84--3.13)   0.154               1.28 (0.65--2.54)           0.475                                   
  Dominant     GG           163        341                 1.00                                            1.00                                    
  AA + AG      128          238        1.13 (0.85--1.50)   0.417               1.08 (0.80--1.44)           0.628                                   
  Recessive    GG + AG      274        557                 1.00                                            1.00                                    
  AA           17           22         1.57 (0.82--3.01)   0.173               1.26 (0.64--2.46)           0.505                                   
  Additive     --           --         --                  1.16 (0.91--1.47)   0.239                       1.09 (0.85--1.39)   0.515               
  rs2072472    Codominant   TT         174                 360                 1.00                                            1.00                 
  CT           96           188        1.06 (0.78--1.43)   0.724               1.09 (0.80--1.50)           0.586                                   
  CC           22           31         1.47 (0.83--2.61)   0.191               1.44 (0.79--2.64)           0.232                                   
  Dominant     TT           174        360                 1.00                                            1.00                                    
  CC + CT      118          219        1.12 (0.84--1.49)   0.459               1.14 (0.85--1.54)           0.382                                   
  Recessive    TT + CT      270        548                 1.00                                            1.00                                    
  CC           22           31         1.44 (0.82--2.54)   0.206               1.40 (0.77--2.53)           0.265                                   
  Additive     --           --         --                  1.14 (0.90--1.43)   0.275                       1.15 (0.91--1.46)   0.254               

95% CI: 95% Confidence interval; OR: Odds ratio; SNP: Single nucleotide polymorphism.

Adjust OR and 95% CI were calculated using a conditional logistic regression adjusted with age. *p* \< 0.05 was considered statistically significant.
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Additionally, we observed a statistically significant association between the rs3218896 polymorphism and endometrial cancer risk. The relative OR of 1.41 (95% CI: 1.00--1.97) showed that the variant heterozygote CT was correlated with a higher risk of developing endometrial carcinoma comparing with the wild‐type homozygous genotype TT. A statistically significant interaction was observed between the variant homozygote CC and heterozygote CT genotypes of rs3218896 for an increased risk of endometrial cancer in the dominant model compared with the TT wild‐type genotype individuals (OR = 1.41, 95% CI: 1.02--1.96, *p* = 0.037). We also found that the SNP rs3218896 was significantly associated with an increased risk of endometrial cancer in the additive model (OR = 1.34, 95% CI: 1.01--1.79, *p* = 0.043). However, no associations between the four *IL‐1R2* polymorphisms (rs11674595, rs719250, rs3218977, and rs2072472) and endometrial cancer risk were observed in the different genetic models.

The results of pair‐wise LD analysis with these six SNPs are shown in Figure [1](#mgg3650-fig-0001){ref-type="fig"}. We observed two small haplotype blocks; first composed of rs11674595, rs4851527, rs719250, and rs3218896; second of rs3218977 and rs2072472. The distributions of the frequencies of the haplotypes TGTC and TACT were significantly different between endometrial cancer and control groups (*p* = 0.031 and *p* = 0.049, respectively). Logistic regression analysis confirmed that the haplotypes TGTC (OR = 0.73, 95% CI: 0.54--0.97) and TACT (OR = 0.79, 95% CI: 0.63--1.00) were significantly associated with decreased endometrial cancer risk after adjusting for age (Table [3](#mgg3650-tbl-0003){ref-type="table"}). Moreover, the haplotype AA was found to be significantly associated with a reduced risk of endometrial cancer before adjusting for age (OR = 0.81, 95% CI: 0.67--0.99, *p* = 0.044) (Table [3](#mgg3650-tbl-0003){ref-type="table"}).

![Haplotype block map for the six SNPs in the *IL‐1R2* gene. Pairwise linkage disequilibrium (LD) measures (D and r^2^) were shown by the LD map. Square background color represents the D'/LOD and the values in cells are r^2^ values (multiplied by 100). Bright red represents very strong LD; white represents no LD; pink represents intermediate LD](MGG3-7-e650-g001){#mgg3650-fig-0001}

###### 

Association between haplotypes of *IL‐1R2* and endometrial cancer risk

  SNP‐ID                                       Haplotype   FA      FU      OR (95%CI)          *p*     Adjust OR (95%CI)   Adjust *p*
  -------------------------------------------- ----------- ------- ------- ------------------- ------- ------------------- ------------
  rs11674595\|rs4851527\|rs719250\|rs3218896   TGTC        0.835   0.866   0.78 (0.59--1.03)   0.080   0.73 (0.54--0.97)   0.031
  rs11674595\|rs4851527\|rs719250\|rs3218896   TGTT        0.848   0.837   1.09 (0.83--1.44)   0.530   1.04 (0.78--1.38)   0.778
  rs11674595\|rs4851527\|rs719250\|rs3218896   TACT        0.266   0.309   0.81 (0.65--1.01)   0.063   0.79 (0.63--1.00)   0.049
  rs11674595\|rs4851527\|rs719250\|rs3218896   CGCT        0.778   0.781   0.98 (0.78--1.24)   0.879   0.98 (0.77--1.25)   0.860
  rs11674595\|rs4851527\|rs719250\|rs3218896   TGCT        0.807   0.829   0.86 (0.66--1.12)   0.257   0.93 (0.71--1.21)   0.577
  rs3218977\|rs2072472                         AG          0.759   0.784   0.87 (0.69--1.10)   0.244   0.86 (0.68--1.10)   0.227
  rs3218977\|rs2072472                         GA          0.75    0.776   0.86 (0.68--1.10)   0.224   0.92 (0.71--1.17)   0.487
  rs3218977\|rs2072472                         AA          0.509   0.56    0.81 (0.67--0.99)   0.044   0.84 (0.68--1.04)   0.105

95% CI: 95% Confidence interval; FA: Frequency in case; FU: Frequency in control; OR: Odds ratio.

OR and 95% CI were calculated using a conditional logistic regression.

*p* value \< 0.05 indicates statistical significance.
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Given that age is a major endometrial cancer risk factor, we further evaluated the association between polymorphisms of *IL‐1R2* and endometrial cancer risk by age stratified analysis (Table [4](#mgg3650-tbl-0004){ref-type="table"}). The CC genotype of rs2072472 was found to be associated with an increased risk of endometrial cancer compared with the TT wild‐type homozygous genotype in age \>54 years old subgroup (OR = 2.28, 95% CI: 1.04--5.00, *p* = 0.040). When compared with the variant homozygote TT and heterozygote CT genotypes, the genotype CC was also found to be associated with an increased risk of endometrial cancer in the recessive model in the subgroup of age \>54 years (OR = 2.33, 95% CI: 1.08--5.03, *p* = 0.032).

###### 

Age stratification analysis of association between rs2072472 and endometrial cancer risk

  Model        Genotype   Age ≤54 years old   Age \>54 years old                                                                             
  ------------ ---------- ------------------- -------------------- ------------------- ------- ----- ------------------- ------------------- -------
  Codominant   TT         83                  238                  1.00                        91    122                 1.00                 
  CT           43         133                 0.94 (0.61--1.46)    0.785               53      55    1.30 (0.82--2.08)   0.268               
  CC           14         18                  2.28 (1.04--5.00)    0.040               8       13    0.77 (0.30--1.96)   0.586               
  Dominant     TT         83                  238                  1.00                        91    122                 1.00                 
  CC + CT      57         151                 1.10 (0.73--1.65)    0.660               61      68    1.20 (0.77--1.86)   0.422               
  Recessive    TT + CT    126                 371                  1.00                        144   177                 1.00                 
  CC           14         18                  2.33 (1.08--5.03)    0.032               8       13    0.71 (0.28--1.77)   0.458               
  Additive     --         --                  --                   1.22 (0.88--1.69)   0.225   --    --                  1.06 (0.75--1.51)   0.729

95% CI: 95% Confidence interval; OR: Odds ratio.

*p* \< 0.05 was considered statistically significant.
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4. DISCUSSION {#mgg3650-sec-0011}
=============

In this study, we investigate the influence of *IL‐1R2* polymorphisms on endometrial cancer susceptibility in the Chinese Han population. Overall analysis results found that rs4851527 was associated with a decreased risk of endometrial cancer; rs3218896 was significantly associated with an increased risk of endometrial cancer. Haplotype analysis confirmed that the haplotypes TGTC and TACT were significantly associated with decreased endometrial cancer risk. Moreover, stratification analysis showed that rs2072472 was associated with an increased risk of endometrial cancer in age \>54 subgroup.

*IL‐1R2* was first characterized by McMahon et al. in 1991 and natively found on neutrophils, B‐cells, monocytes, and macrophages (McMahan et al., [1991](#mgg3650-bib-0016){ref-type="ref"}). *IL‐1R2* serves as an endogenous inhibitor of *IL‐1* signaling by competing with *IL‐1R1*for *IL‐1*, and by subsequently forming a complex with IL‐1RAcP, thereby sequestering both the ligand and the accessory protein required for signal transduction (Schluter, Schelmbauer, Karram, & Mufazalov, [2018](#mgg3650-bib-0022){ref-type="ref"}). Additionally, *IL‐1R2*exists in both a membrane bound and soluble form (sIL‐1R2) that has biological properties similar to both a decoy receptor and a binding protein (Peters et al., [2013](#mgg3650-bib-0019){ref-type="ref"}). Study found that *IL‐1R2* regulates the cell metabolism and the response of immune inflammation induced by many cytokines (Dinarello, [1994](#mgg3650-bib-0009){ref-type="ref"}). These suggest that *IL‐1R2* is an important mediator involved in many cytokine induced immune and inflammatory responses*.*Inflammation aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and thus initiate and promote neoplastic transformation (Mantovani, Allavena, Sica, & Balkwill, [2008](#mgg3650-bib-0015){ref-type="ref"}). It has reported that a proinflammatory milieu can also directly increase estrogen production, and then promotes the development of endometrial cancer (Modugno et al., [2005](#mgg3650-bib-0017){ref-type="ref"}).

In this study, our results observed that rs4851527 and rs2072472 were associated with decreased risk of endometrial cancer, and rs3218896 was significantly associated with an increased risk of endometrial cancer. Previous study reported that the SNP rs4851527 was associated with an increased risk of IgA nephropathy in the over‐dominant model (GA vs. GG‐AA) (Xie et al., [2015](#mgg3650-bib-0025){ref-type="ref"}). However, association studies indicated that rs4851527 was associated with decreased risk of tuberculosis (Ren et al., [2018](#mgg3650-bib-0021){ref-type="ref"}) and ankylosing spondylitis (Xia et al., [2015](#mgg3650-bib-0025){ref-type="ref"}). No significant association was found between the two SNPs (rs3218896 and rs2072472) and risk of IgA nephropathy (Xie et al., [2017](#mgg3650-bib-0026){ref-type="ref"}), tuberculosis (Ren et al., [2018](#mgg3650-bib-0021){ref-type="ref"}), and breast cancer (Zuo et al., [2018](#mgg3650-bib-0030){ref-type="ref"}). Moreover, no significant association was also found between rs2072472 and the risk of ankylosing spondylitis (Xia et al., [2015](#mgg3650-bib-0025){ref-type="ref"}) and endometriosis (Chun et al., [2012](#mgg3650-bib-0008){ref-type="ref"}). Previous study reported that rs3218977 was found to be associated with a 0.71‐fold decrease risk of IgA nephropathy in the dominant model (GA‐GG vs. AA) (Xie et al., [2017](#mgg3650-bib-0026){ref-type="ref"}). A case‐control association study found that the SNP rs3218977 was associated with an increased risk of aggressive periodontitis in the additive model in the Japanese (Kamei et al., [2014](#mgg3650-bib-0011){ref-type="ref"}). However, rs3218977 was associated with an increased risk of tuberculosis in the dominant model (Ren et al., [2018](#mgg3650-bib-0021){ref-type="ref"}). However, no significant association was also found between rs3218977 and risk of endometrial cancer in this study. These inconsistencies may be explained by the genetic polymorphism which may have different effects on diseases.

Some potential limitations of the present study should be considered when interpreting the results. First, our result is the first to find that the *IL‐1R2* polymorphisms were associated with the risk of endometrial cancer in the Chinese Han population. Therefore, additional studies are needed to confirm the association between *IL‐1R2*polymorphisms and endometrial cancer risk with large samples. Second, the potential risk factors such as early menarche, unopposed estrogen, late menopause, and obesity were not analyzed in this study due to the lack of relevant clinical data. More clinical and experimental data were needed to be collected to help us understand better the role of *IL‐1R2*polymorphisms in the development of endometrial cancer. Third, the biological functions of these SNPs were not analyzed. The expression level of the *IL‐1R2* gene should also be measured in future studies to assess the effects of polymorphisms on *IL‐1R2* gene.

5. CONCLUSIONS {#mgg3650-sec-0012}
==============

In conclusion, the present study results indicated that rs4851527, rs3218896, and rs2072472 in the *IL‐1R2*gene were associated with endometrial cancer susceptibility in the Chinese Han population. These findings suggested that *IL‐1R2*polymorphisms may contribute to the development of endometrial cancer. However, further studies are required to confirm the results of the study with a large sample and investigate the detailed mechanisms of the variants that affect *IL‐1R2* gene function.
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